Tomotaka Wakazono1, Masahiro Miyake1, Kenji Yamashiro2, Munemitsu Yoshikawa1, Nagahisa Yoshimura1. 1. Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Kawahara, Shogoin, Sakyo, Kyoto, 606-8507, Japan. 2. Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Kawahara, Shogoin, Sakyo, Kyoto, 606-8507, Japan. yamashro@kuhp.kyoto-u.ac.jp.
Abstract
PURPOSE: To investigate the role of SCO2 in extreme myopia of Japanese patients. METHODS: In total, 101 Japanese patients with extreme myopia (axial length of ≥30 mm) OU at the Kyoto University Hospital were included in this study. Exon 2 of SCO2 was sequenced by conventional Sanger sequencing. The detected variants were assessed using in silico prediction programs: SIFT, PolyPhen-2 and MutationTaster. To determine the frequency of the mutations in normal subjects, we referred to the 1000 Genomes Project data and the Human Genetic Variation Database (HGVD) in the Human Genetic Variation Browser. RESULTS: The average age of the participants was 62.9 ± 12.7 years. There were 31 males (30.7 %) and 70 females. Axial lengths were 31.76 ± 1.17 mm OD and 31.40 ± 1.07 mm OS, and 176 eyes (87.6 %) out of 201 eyes had myopic maculopathy of grade 2 or more. Among the 101 extremely myopic patients, one mutation (c.290 C > T;p.Ala97Val) in SCO2 was detected. This mutation was not found in the 1000 Genomes Project data or HGVD data. Variant type of the mutation was nonsynonymous. Although the SIFT prediction score was 0.350, the PolyPhen-2 probability was 0.846, thus predicting its pathogenicity to be possibly damaging. MutationTaster PhyloP was 1.268, suggesting that the mutation is conserved. CONCLUSIONS: We identified one novel possibility of an extreme myopia-causing mutation in SCO2. No other disease-causing mutation was found in 101 extremely myopic Japanese patients, suggesting that SCO2 plays a limited role in Japanese extreme myopia. Further investigation is required for better understanding of extreme myopia.
PURPOSE: To investigate the role of SCO2 in extreme myopia of Japanese patients. METHODS: In total, 101 Japanese patients with extreme myopia (axial length of ≥30 mm) OU at the Kyoto University Hospital were included in this study. Exon 2 of SCO2 was sequenced by conventional Sanger sequencing. The detected variants were assessed using in silico prediction programs: SIFT, PolyPhen-2 and MutationTaster. To determine the frequency of the mutations in normal subjects, we referred to the 1000 Genomes Project data and the Human Genetic Variation Database (HGVD) in the Human Genetic Variation Browser. RESULTS: The average age of the participants was 62.9 ± 12.7 years. There were 31 males (30.7 %) and 70 females. Axial lengths were 31.76 ± 1.17 mm OD and 31.40 ± 1.07 mm OS, and 176 eyes (87.6 %) out of 201 eyes had myopic maculopathy of grade 2 or more. Among the 101 extremely myopic patients, one mutation (c.290 C > T;p.Ala97Val) in SCO2 was detected. This mutation was not found in the 1000 Genomes Project data or HGVD data. Variant type of the mutation was nonsynonymous. Although the SIFT prediction score was 0.350, the PolyPhen-2 probability was 0.846, thus predicting its pathogenicity to be possibly damaging. MutationTaster PhyloP was 1.268, suggesting that the mutation is conserved. CONCLUSIONS: We identified one novel possibility of an extreme myopia-causing mutation in SCO2. No other disease-causing mutation was found in 101 extremely myopic Japanese patients, suggesting that SCO2 plays a limited role in Japanese extreme myopia. Further investigation is required for better understanding of extreme myopia.
Authors: Kristien P Hoornaert; Inge Vereecke; Chantal Dewinter; Thomas Rosenberg; Frits A Beemer; Jules G Leroy; Laila Bendix; Erik Björck; Maryse Bonduelle; Odile Boute; Valerie Cormier-Daire; Christine De Die-Smulders; Anne Dieux-Coeslier; Hélène Dollfus; Mariet Elting; Andrew Green; Veronica I Guerci; Raoul C M Hennekam; Yvonne Hilhorts-Hofstee; Muriel Holder; Carel Hoyng; Kristi J Jones; Dragana Josifova; Ilkka Kaitila; Suzanne Kjaergaard; Yolande H Kroes; Kristina Lagerstedt; Melissa Lees; Martine Lemerrer; Cinzia Magnani; Carlo Marcelis; Loreto Martorell; Michèle Mathieu; Meriel McEntagart; Angela Mendicino; Jenny Morton; Gabrielli Orazio; Véronique Paquis; Orit Reish; Kalle O J Simola; Sarah F Smithson; Karen I Temple; Elisabeth Van Aken; Yolande Van Bever; Jenneke van den Ende; Johanna M Van Hagen; Leopoldo Zelante; Riina Zordania; Anne De Paepe; Bart P Leroy; Marc De Buyzere; Paul J Coucke; Geert R Mortier Journal: Eur J Hum Genet Date: 2010-02-24 Impact factor: 4.246
Authors: Chris B Roberts; Yoshimune Hiratsuka; Masakazu Yamada; M Lynne Pezzullo; Katie Yates; Shigeru Takano; Kensaku Miyake; Hugh R Taylor Journal: Arch Ophthalmol Date: 2010-06
Authors: Donald O Mutti; Margaret E Cooper; Sarah O'Brien; Lisa A Jones; Mary L Marazita; Jeffrey C Murray; Karla Zadnik Journal: Mol Vis Date: 2007-06-28 Impact factor: 2.367
Authors: Weihua Meng; Jacqueline Butterworth; Declan T Bradley; Anne E Hughes; Vincent Soler; Patrick Calvas; Francois Malecaze Journal: Invest Ophthalmol Vis Sci Date: 2012-12-05 Impact factor: 4.799
Authors: Khanh-Nhat Tran-Viet; Elizabeth St Germain; Vincent Soler; Caldwell Powell; Sing-Hui Lim; Thomas Klemm; Seang Mei Saw; Terri L Young Journal: Mol Vis Date: 2012-04-12 Impact factor: 2.367
Authors: Eva González-Iglesias; Ana López-Vázquez; Susana Noval; María Nieves-Moreno; María Granados-Fernández; Natalia Arruti; Irene Rosa-Pérez; Marta Pacio-Míguez; Victoria E F Montaño; Patricia Rodríguez-Solana; Angela Del Pozo; Fernando Santos-Simarro; Elena Vallespín Journal: Int J Mol Sci Date: 2022-04-11 Impact factor: 6.208